(Q37271814)

19 August 2017

1 reference

title

What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma? (English)

1 reference

positron emission tomography

19 August 2017

main subject

1 reference

Rodney J Hicks

2

0 references

author name string

Saar Gill

series ordinal

1

1 reference

19 August 2017

John F Seymour

series ordinal

3

1 reference

19 August 2017

publication date

1 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

49

1 reference

19 August 2017

issue

9

1 reference

19 August 2017

page(s)

1653-1656

1 reference

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Therapeutic options in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Overview of early response assessment in lymphoma with FDG-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Utility of FDG-PET scanning in lymphoma by WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Positron emission tomography in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Limited-stage mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Central nervous system involvement in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802311433

10.1080/10428190802311433

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference